IAM
AXSM icon

Iridian Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Iridian Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.4M Sell
67,491
-6,292
-9% -$1.09M 4.62% 8
2025
Q4 		$13.5M Sell
73,783
-9,770
-12% -$1.36M 4.96% 8
2025
Q3 		$10.1M Sell
83,553
-8,208
-9% -$925K 3.99% 10
2025
Q2 		$9.58M Sell
91,761
-14,551
-14% -$1.54M 3.32% 9
2025
Q1 		$12.4M Sell
106,312
-18,767
-15% -$2.14M 3.89% 9
2024
Q4 		$10.6M Sell
125,079
-1,724
-1% -$159K 2.82% 12
2024
Q3 		$11.4M Sell
126,803
-102
-0.1% -$8.9K 2.44% 15
2024
Q2 		$10.2M Sell
126,905
-1,937
-2% -$143K 2.31% 16
2024
Q1 		$10.3M Sell
128,842
-9,495
-7% -$797K 2.02% 14
2023
Q4 		$11M Sell
138,337
-6,696
-5% -$448K 2% 12
2023
Q3 		$10.1M Sell
145,033
-167,375
-54% -$12.5M 2.05% 14
2023
Q2 		$22.4M Buy
312,408
+21,636
+7% +$1.6M 2.09% 13
2023
Q1 		$17.9M Sell
290,772
-27,839
-9% -$1.83M 1.47% 18
2022
Q4 		$24.6M Sell
318,611
-82,497
-21% -$4.93M 2.37% 15
2022
Q3 		$17.9M Sell
401,108
-141,770
-26% -$7.08M 1.78% 23
2022
Q2 		$20.8M Buy
542,878
+25,298
+5% +$800K 1.7% 24
2022
Q1 		$21.4M Sell
517,580
-92,484
-15% -$2.87M 1.49% 27
2021
Q4 		$23M Sell
610,064
-813,589
-57% -$29.9M 1.41% 32
2021
Q3 		$46.9M Sell
1,423,653
-891,610
-39% -$34.7M 1.43% 32
2021
Q2 		$156M Sell
2,315,263
-95,340
-4% -$5.72M 2.73% 11
2021
Q1 		$136M Buy
2,410,603
+346,445
+17% +$24.4M 2.33% 15
2020
Q4 		$168M Buy
2,064,158
+341,335
+20% +$25.5M 3.06% 8
2020
Q3 		$123M Buy
1,722,823
+636,987
+59% +$49.6M 2.68% 15
2020
Q2 		$89.3M Sell
1,085,836
-86,178
-7% -$6.63M 1.97% 24
2020
Q1 		$69M Buy
1,172,014
+517,775
+79% +$42.2M 1.67% 27
2019
Q4 		$67.6M Buy
654,239
+566,738
+648% +$22.9M 1.11% 37
2019
Q3 		$1.77M Sell
87,501
-7,100
-8% -$182K 0.03% 49
2019
Q2 		$2.44M Buy
94,601
+57,471
+155% +$1.15M 0.04% 51
2019
Q1 		$528K Buy
+37,130
New +$345K 0.01% 67

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Iridian Asset Management's AXSM Position: Q1 2026 in Review

Iridian Asset Management reduced its Axsome Therapeutics (AXSM) stake by 8.5% in Q1 2026, selling an estimated $1.09M and leaving 67,491 shares worth $11.4M. The position accounts for 4.62% of the portfolio, ranked #8.

Iridian Asset Management first reported a position in AXSM in Q1 2019 and has held it in 29 quarters since. The position peaked at $168M in Q4 2020. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Iridian Asset Management held 67,491 shares of Axsome Therapeutics worth $11.4M as of Q1 2026.
  • Iridian Asset Management sold 6,292 Axsome Therapeutics shares in Q1 2026, an estimated $1.09M.
  • Axsome Therapeutics made up 4.62% of Iridian Asset Management's portfolio in Q1 2026, its #8 holding.
  • Iridian Asset Management first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • Iridian Asset Management's Axsome Therapeutics position peaked at $168M in Q4 2020.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Iridian Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.